Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (NASDAQ: VVOS) has launched its new patient management software, AireO2, aimed at improving the diagnosis and treatment of obstructive sleep apnea (OSA). With around 1 billion people affected by OSA, the software enhances healthcare professionals’ billing services and operational efficiency. CEO Kirk Huntsman emphasized that AireO2 will help manage more patients effectively. The platform is poised to drive revenue for Vivos beyond its existing services, potentially addressing the needs of OSA-focused healthcare providers.
Vivos Therapeutics announced the closing of its IPO, issuing 4,025,000 shares at $6.00 each, yielding gross proceeds of $24.15 million. The offering included 3,500,000 initial shares plus 525,000 additional shares from underwriters’ options. Roth Capital Partners led the offering, with Craig-Hallum Capital Group and National Securities Corporation as co-managers. The SEC had declared the registration effective on December 10, 2020, with a final prospectus filed on December 14, 2020. Vivos specializes in non-invasive solutions for sleep disordered breathing.